Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conventional immunosuppression and co-stimulation blockade.

A B Adams1, T C Pearson, C P Larsen

  • 1The Carlos and Marguerite Mason Transplantation Research Center, Department of Surgery, Emory University School of Medicine, 5105 Woodruff Memorial Research Building, 1639 Pierce Drive, Atlanta, GA 30322, USA.

Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|May 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Purified Human Pancreatic Islets, CIT Culture Media with Lisofylline or Exenatide.

CellR4-- repair, replacement, regeneration, & reprogramming·2019
Same author

Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2018
Same author

Clinicopathologic Features of Membranous-Like Glomerulopathy With Masked IgG Kappa Deposits.

Kidney international reports·2017
Same author

Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017

New immunology therapies aim to improve long-term organ transplant success by targeting T-cell activation. These novel approaches may reduce side effects associated with conventional immunosuppression, potentially leading to indefinite donor tissue acceptance.

Area of Science:

  • Immunology
  • Transplantation Science

Background:

  • Conventional immunosuppression offers short-term success in organ transplantation but has inadequate long-term outcomes.
  • Non-specific immunosuppressants increase risks of malignancy, infection, and drug-specific side effects.

Purpose of the Study:

  • To explore novel immunotherapies for organ transplantation.
  • To investigate strategies for promoting indefinite donor tissue acceptance and eliminating lifelong drug therapy.

Main Methods:

  • Focus on identifying co-stimulatory signals critical for T-cell activation.
  • Evaluating the compatibility and synergistic effects of new agents with conventional therapeutics.

Main Results:

  • Co-stimulatory blockade presents new possibilities for controlling the alloimmune response.

Related Experiment Videos

  • Combination therapy shows synergistic immunosuppressive properties.
  • Conventional agents may antagonize co-stimulatory blockade's effects on T-cell hyporesponsiveness.

    • Conclusions:

    • Novel immunotherapies targeting T-cell activation hold promise for improving long-term organ transplant outcomes.
    • Careful consideration of conventional agent interactions is necessary for optimizing tolerance induction.